Belarus-produced Sputnik V vaccine to become available for use by June 2022
<p> MINSK, Nov 12 - PrimePress. The Russian-developed Sputnik V vaccine produced as part of Belarus’ full-cycle production project will be available for use by June 2022. Belarus’ Prime Minister Roman Golovchenko made a statement to this effect during his visit to the pharmaceutical company Belmedpreparaty on 12 November, the government’s press-service reports. </p> <p> </p> <p> The company presented an investment project to launch a full-cycle pharmaceutical production of the Sputnik V vaccine in Belarus. </p> <p> </p> <p> “The project is proceeding at a fast pace. We are now at an intermediate stage. The installation of world-class biotechnological equipment is nearing completion. The first validation batch will be rolled out here in December. This is 10% of the commercial batch that will be stored and tested for stability. If everything goes on well, we will embark on registration procedures in Belarus and Russia. In line with the schedule, this vaccine is to be available for use in Belarus and other countries by the beginning of next summer. The estimated total output will exceed 10 million doses per year, of which 4 million doses are designed for Belarus,” Golovchenko said. </p> <p> </p> <p> In his words, if necessary the facility may be used for producing not only Sputnik V, but also other modern biological products. “The vaccine will be the first pharmaceutical product to be made on these premises, but due to multi-purpose equipment it will possible to roll out a wide range of biological products in demand on the market. This facility is unique for Belarus in terms of pharmaceutical and biotechnological equipment, a real breakthrough,” he said. </p> <p> </p> <p> Belmedpreparaty CEO Sergey Belyayev informed that the company is working to launch a full-cycle production of Sputnik V: from biological production of the active substance to the production of a finished vaccine in the form of ampoules or vials. The facility is expected to reach its design capacity in 2022-2023. End </p>
2021-11-13
Primepress
Belarus-produced Sputnik V vaccine to become available for use by June 2022
MINSK, Nov 12 - PrimePress. The Russian-developed Sputnik V vaccine produced as part of Belarus’ full-cycle production project will be available for use by June 2022. Belarus’ Prime Minister Roman Golovchenko made a statement to this effect during his visit to the pharmaceutical company Belmedpreparaty on 12 November, the government’s press-service reports.
The company presented an investment project to launch a full-cycle pharmaceutical production of the Sputnik V vaccine in Belarus.
“The project is proceeding at a fast pace. We are now at an intermediate stage. The installation of world-class biotechnological equipment is nearing completion. The first validation batch will be rolled out here in December. This is 10% of the commercial batch that will be stored and tested for stability. If everything goes on well, we will embark on registration procedures in Belarus and Russia. In line with the schedule, this vaccine is to be available for use in Belarus and other countries by the beginning of next summer. The estimated total output will exceed 10 million doses per year, of which 4 million doses are designed for Belarus,” Golovchenko said.
In his words, if necessary the facility may be used for producing not only Sputnik V, but also other modern biological products. “The vaccine will be the first pharmaceutical product to be made on these premises, but due to multi-purpose equipment it will possible to roll out a wide range of biological products in demand on the market. This facility is unique for Belarus in terms of pharmaceutical and biotechnological equipment, a real breakthrough,” he said.
Belmedpreparaty CEO Sergey Belyayev informed that the company is working to launch a full-cycle production of Sputnik V: from biological production of the active substance to the production of a finished vaccine in the form of ampoules or vials. The facility is expected to reach its design capacity in 2022-2023. End